DepoMed (DEPO) Reports Q3 EPS of 3c, Offers Guidance

DepoMed (NASDAQ: DEPO) reported Q3 EPS of $0.03, may not compare to the analyst estimate of ($0.04). Revenue for the quarter came in at $51.5 million versus the consensus estimate of $41.5 million.

DepoMed sees FY2014 EPS of $0.06-$0.14, may not compare toi the consensus of $0.47. DepoMed sees FY2014 revenue of $232-242 million, versus the consensus of $231.47 million.

For earnings history and earnings-related data on DepoMed (DEPO) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
• FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer